Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
Orchestra BioMed Holdings (Nasdaq: OBIO) has appointed John Mack to its Board of Directors, effective July 29, 2024. Mack brings over 30 years of experience in medical devices, healthcare technology, and finance. He most recently served as President of Cardiac Surgery at Medtronic, where he led the division to market leadership. His previous roles at Medtronic included Vice President & General Manager of Extracorporeal Therapies and Vice President of Business Development, Strategy & Portfolio Management.
David Hochman, Chairman and CEO of Orchestra BioMed, expressed confidence in Mack's ability to contribute to the company's growth and leverage its partnership-enabled business model. Mack's extensive experience in cardiovascular therapy markets and his industry-wide relationships are expected to be valuable assets to the company.
Orchestra BioMed Holdings (Nasdaq: OBIO) ha nominato John Mack nel suo Consiglio di Amministrazione, con effetto dal 29 luglio 2024. Mack porta con sé oltre 30 anni di esperienza nel settore dei dispositivi medici, della tecnologia sanitaria e della finanza. Recentemente, ha ricoperto il ruolo di Presidente della Chirurgia Cardiaca presso Medtronic, dove ha guidato la divisione verso la leadership di mercato. Le sue esperienze precedenti in Medtronic includono le posizioni di Vice Presidente e Direttore Generale delle Terapie Extracorporee e Vice Presidente dello Sviluppo Aziendale, Strategia e Gestione del Portafoglio.
David Hochman, Presidente e CEO di Orchestra BioMed, ha espresso fiducia nella capacità di Mack di contribuire alla crescita dell'azienda e di sfruttare il suo modello di business facilitato dalle partnership. Si prevede che l'ampia esperienza di Mack nei mercati della terapia cardiaca e le sue relazioni in tutta l'industria siano asset preziosi per l'azienda.
Orchestra BioMed Holdings (Nasdaq: OBIO) ha nombrado a John Mack en su Junta Directiva, con efecto a partir del 29 de julio de 2024. Mack aporta más de 30 años de experiencia en dispositivos médicos, tecnología de la salud y finanzas. Recientemente, se desempeñó como Presidente de Cirugía Cardíaca en Medtronic, donde lideró la división hacia el liderazgo en el mercado. Sus roles anteriores en Medtronic incluyeron Vicepresidente y Gerente General de Terapias Extracorpóreas y Vicepresidente de Desarrollo Empresarial, Estrategia y Gestión de Portafolio.
David Hochman, Presidente y CEO de Orchestra BioMed, expresó confianza en la capacidad de Mack para contribuir al crecimiento de la empresa y aprovechar su modelo de negocio habilitado por partnerships. Se espera que la amplia experiencia de Mack en los mercados de terapia cardiovascular y sus relaciones en toda la industria sean activos valiosos para la empresa.
오케스트라 바이오 메드 홀딩스(Nasdaq: OBIO)는 존 맥을 이사로 선임했으며, 2024년 7월 29일부터 발효됩니다. 맥은 의료 기기, 헬스케어 기술 및 금융 분야에서 30년 이상의 경험을 가지고 있습니다. 그는 최근 메드트로닉의 심장 수술 부사장으로 재직하며 해당 부서를 시장 선두자로 이끌었습니다. 메드트로닉에서의 이전 역할로는 체외 치료의 부사장 및 총괄 매니저와 사업 개발, 전략 및 포트폴리오 관리를 담당한 부사장이 포함됩니다.
오케스트라 바이오 메드의 회장 겸 CEO인 데이비드 호흐만은 맥이 회사의 성장에 기여하고 파트너십 기반 비즈니스 모델을 활용할 수 있는 능력에 대해 자신감을 표명했습니다. 맥의 심혈관 치료 시장에서의 폭넓은 경험과 업계 전반에 걸친 관계는 회사에 귀중한 자산이 될 것으로 예상됩니다.
Orchestra BioMed Holdings (Nasdaq: OBIO) a nommé John Mack au sein de son Conseil d'Administration, à compter du 29 juillet 2024. Mack apporte plus de 30 ans d'expérience dans les dispositifs médicaux, la technologie de la santé et la finance. Il a récemment occupé le poste de Président de la Chirurgie Cardiaque chez Medtronic, où il a conduit la division à la tête du marché. Ses rôles précédents chez Medtronic comprenaient Vice-Président et Directeur Général des Thérapies Extracorporelles et Vice-Président du Développement Commercial, de la Stratégie et de la Gestion de Portefeuille.
David Hochman, Président et Directeur Général d'Orchestra BioMed, a exprimé sa confiance dans la capacité de Mack à contribuer à la croissance de l'entreprise et à tirer parti de son modèle commercial basé sur les partenariats. L'expérience approfondie de Mack sur les marchés de la thérapie cardiovasculaire et ses relations à l'échelle de l'industrie devraient constituer des atouts précieux pour l'entreprise.
Orchestra BioMed Holdings (Nasdaq: OBIO) hat John Mack in den Vorstand berufen, der am 29. Juli 2024 in Kraft tritt. Mack bringt über 30 Jahre Erfahrung im Bereich medizinische Geräte, Gesundheitstechnologie und Finanzen mit. Zuletzt war er Präsident der Herzchirurgie bei Medtronic, wo er die Abteilung zur Marktführerschaft führte. Zu seinen vorherigen Positionen bei Medtronic gehörten Vizepräsident und Geschäftsführer für extrakorporale Therapien sowie Vizepräsident für Geschäftsentwicklung, Strategie und Portfoliomanagement.
David Hochman, Vorsitzender und CEO von Orchestra BioMed, äußerte Vertrauen in Macks Fähigkeit, zum Wachstum des Unternehmens beizutragen und das partnership-basierte Geschäftsmodell zu nutzen. Macks umfangreiche Erfahrung im Bereich der kardiovaskulären Therapie und seine branchenweiten Beziehungen werden als wertvolle Ressourcen für das Unternehmen angesehen.
- Appointment of John Mack, a seasoned industry expert with over 30 years of experience
- Mack's successful track record in leading Medtronic's Cardiac Surgery division to market leadership
- Potential for leveraging Mack's industry relationships to identify growth opportunities
- Mack's expertise aligns with Orchestra BioMed's focus on high-impact therapeutic devices
- None.
- John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors
- Most recently, Mr. Mack served as Medtronic’s President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management
NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years of medical device, healthcare technology, and finance experience to the Company. Mr. Mack most recently served as President of Cardiac Surgery at Medtronic plc., where he successfully led the division to market leadership. During his tenure at Medtronic, he also served as Vice President & General Manager, Extracorporeal Therapies and Vice President, Business Development, Strategy & Portfolio Management where he led the business development operations for the coronary and structural heart business, a
“John is an esteemed member of the medical device community, and we are confident his extensive operational and strategic experience and proven leadership will be tremendous assets to the Orchestra BioMed Board,” said David Hochman, Chairman and CEO of Orchestra BioMed. “John’s outstanding track record includes helping guide Medtronic to market leadership in structural cardiology and strengthening their market leading position in cardiac surgery. He has a deep understanding of critical cardiovascular therapy markets and the role that high-impact, novel therapeutic devices can play in growing and transforming these markets. We expect his strong, industry-wide relationships to help us identify avenues for growth. We look forward to achieving new milestones together and realizing key opportunities to leverage our partnership-enabled business model.”
Mr. Mack commented, “I am honored to join Orchestra BioMed’s Board of Directors and enthusiastically support its mission to accelerate medical innovations and deliver life-changing therapies to patients. Having spent many years in the field, I have seen firsthand the transformative impact that innovation and the right strategic business relationships can have on patient care. The Company has real potential to make a significant contribution to the medical device landscape with its promising pipeline and partnership-enabled business model. I look forward to working with this dynamic organization and its team of visionaries.”
Mr. Mack is currently a member of the Board of Directors at Minneapolis Heart Institute Foundation, one of the leading nonprofit cardiovascular and vascular research and education institutions in the country. In addition to his role at Medtronic, Mr. Mack has served on the boards of MC3 Cardiopulmonary and the Twin Cities American Heart Association. His leadership has been recognized with awards such as the Wallin Leadership Award and the Medtronic Star of Excellence Award.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to the impact of Mr. Mack’s appointment on the Company’s collaboration with Medtronic and the Company’s ability to identify avenues for growth, statements relating to the potential efficacy and safety of the Company’s commercial product candidates, the ability of the Company’s partnerships to accelerate clinical development, and the Company’s late-stage development programs, strategic partnerships and plans to expand its product pipeline. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 27, 2024 and in the Company’s subsequently filed quarterly reports on Form 10-Q.
The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.
Investor Contact:
Bob Yedid
LifeSci Advisors
(516) 428-8577
Bob@lifesciadvisors.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
(484) 682-4892
Kkirkellis@orchestrabiomed.com
FAQ
Who is the new Board member appointed by Orchestra BioMed (OBIO)?
What was John Mack's most recent position before joining Orchestra BioMed's (OBIO) Board?
How might John Mack's appointment benefit Orchestra BioMed (OBIO)?
What other roles has John Mack held at Medtronic before joining Orchestra BioMed's (OBIO) Board?
